|
Modality
|
Parameters
|
PFS ≤ 4 months
|
PFS > 4 months
|
p value
|
|---|
|
CT
|
Sum of uni-dimensional measurements of target lesions (cm)
|
74.6 ± 42.8
|
69.2 ± 23.2
|
0.87
|
|
FDG
|
Highest SUVmax
|
12.8 ± 5.6
|
11.7 ± 4.4
|
0.95
|
|
Sum of SUVmax
|
38.8 ± 41.6
|
28.6 ± 21.4
|
0.90
|
|
MTV
|
138.0 ± 129.0
|
57.6 ± 43.5
|
0.19
|
|
TLG
|
707.9 ± 701.7
|
292.3 ± 240.7
|
0.21
|
|
SUL
|
10.0 ± 4.8
|
7.6 ± 3.3
|
0.28
|
|
%Δhighest SUVmax
|
− 12.2 ± 37.8
|
− 12.0 ± 80.7
|
0.42
|
|
%Δsum of SUVmax
|
− 19.2 ± 39.8
|
− 6.4 ± 85.1
|
0.79
|
|
%ΔMTV
|
− 10.4 ± 59.4
|
− 29.1 ± 45.8
|
0.42
|
|
%ΔTLG
|
− 10.9 ± 99.7
|
− 32.4 ± 79.0
|
0.33
|
|
%ΔSUL
|
− 26.8 ± 47.5
|
− 34.4 ± 66.1
|
0.39
|
|
4DST
|
Highest SUVmax
|
6.8 ± 2.4
|
5.7 ± 1.7
|
0.11
|
|
Sum of SUVmax
|
19.4 ± 17.8
|
22.8 ± 21.0
|
0.84
|
|
MTV
|
127.7 ± 127.8
|
50.3 ± 29.2
|
0.06
|
|
TLP
|
384.4 ± 371.0
|
158.4 ± 116.0
|
0.09
|
|
%Δhighest SUVmax
|
11.9 ± 37.3
|
− 5.6 ± 47.9
|
0.33
|
|
%Δsum of SUVmax
|
9.1 ± 49.5
|
− 18.6 ± 56.9
|
0.19
|
|
%ΔMTV
|
− 18.9 ± 45.7
|
− 36.9 ± 52.4
|
0.33
|
|
%ΔTLP
|
− 5.2 ± 77.9
|
− 32.9 ± 60.3
|
0.37
|
- MTV metabolic tumor volume, TLG total lesion glycolysis, SUL standardized uptake value normalized by lean body mass, TLP total lesion proliferation
